医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

EdiGene Announces

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration

バイオテクノロジーヘルスケア腫瘍学遺伝学　 TimeLine: Cas 9 Gene-editing EdiGene Announces Hematopoietic Stem Cell Therapy ET-01 in its CRISPR thalassemia Accepted for

2020年10月27日

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration

バイオテクノロジーヘルスケア腫瘍学遺伝学　 TimeLine: Cas 9 Gene-editing EdiGene Announces Hematopoietic Stem Cell Therapy ET-01 in its CRISPR thalassemia Accepted for

2020年10月27日